Health
Sequana Medical Announces Presentation on Recompensation of Decompensated Cirrhosis Following alfapump® Placement at EASL Congress 2026
Ghent, Belgium, May 29, 2026 (GLOBE NEWSWIRE) -- Post-hoc analysis from the POSEIDON study demonstrates long-term resolution of ascites and early signs of liver function recovery in over 20% of patients with alfapump in situ for over six monthsThis important finding builds upon the virtual elimination of therapeutic paracentesis and an improvement in quality of life in the POSEIDON study previously reported1 Ghent, Belgium, 29 May 2026 - Sequana Medical NV (Euronext Brussels: SEQUA, the “Company
About this update from Sequana Medical N.v
[{"type":"image","alt":"Sequana Medical NV","displaySize":"","headline":null,"caption":"Sequana Medical NV","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":64,"url":"https://media.zenfs.com/en/globenewswire.com/eebd983759ebc3a966954513471e9960"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ZrIpOehiKz_M4rbjFpbY5A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkw/https://media.zenfs.com/en/globenewswire.com/eebd983759ebc3a966954513471e9960","width":300,"height":64},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/ZrIpOehiKz_M4rbjFpbY5A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkw/https://media.zenfs.com/en/globenewswire.com/eebd983759ebc3a966954513471e9960","width":300,"height":64}},"lazy":false},{"type":"text","content":"Ghent, Belgium, May 29, 2026 (GLOBE NEWSWIRE) --","length":48,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Post-hoc analysis from the POSEIDON study demonstrates long-term resolution of ascites and early signs of liver function recovery in over 20% of patients with alfapump in situ for over six months","length":195,"tagName":"p"}]},{"val":[{"type":"text","content":"This important finding builds upon the virtual elimination of therapeutic paracentesis and an improvement in quality of life in the POSEIDON study previously reported1","length":167,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":362,"olType":false},{"type":"text","content":"Ghent, Belgium, 29 May 2026 - Sequana Medical NV (Euronext Brussels: SEQUA, the “Company” or “Sequana Medical”), a pioneer in the treatment of drug-resistant fluid overload in liver disease, heart failure and cancer, today announced the presentation of data from a post-hoc analysis of the Phase 3 POSEIDON study of alfapump at the European Association for the Study of the Liver (EASL) Congress 2026 in Barcelona, Spain. EASL Congress is one of the world’s premier events dedicated to liver health, bringing together physicians, scientists, and allied health professionals from across the globe to share knowledge and highlight breakthroughs across the full spectrum of hepatology. The poster, titled “Recompensation of decompensated cirrhosis and long-term resolution of ascites in patients undergoing alfapump placement: experience from the multi-centre POSEIDON study,” was presented in the Portal Hypertension session.","length":923,"tagName":"p...